| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.caplinpoint.net | |
| Market Cap | 6,028.42 Cr. | |
| Enterprise Value(EV) | 5,462.46 Cr. | 2022-03 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 39.56 | Trailing Twelve Months Ending 2022-03 |
| Price-Earning Ratio (PE) | 20.11 | Trailing Twelve Months Ending 2022-03 |
| Industry PE | 28.47 | Trailing Twelve Months Ending 2022-03 |
| Book Value / Share | 195.77 | Trailing Twelve Months Ending 2022-03 |
| Price to Book Value | 4.07 | Calculated using Price: 796.35 |
| Dividend Yield | 0.25 | Period Ending 2021-03 |
| No. of Shares Subscribed | 7.58 Cr. | 75,800,542 Shares |
| FaceValue | 2 | |
| Company Profile | ||
|
Caplin Point Laboratories was established in 1990 to manufacture a range of ointments, creams and other external applications. The Company was listed in 1994; the IPO proceeds were deployed in a manufacturing facility in Pondicherry. The promoters exposed their lives to physical risk when they ventured into war-affected countries more than two decades ago. The Company ventured into the emerging markets of West Africa, Latin America and The Caribbean to market finished formulations. The Company’s asset-light marketing business model has helped generate the resources to build world-class infrastructure. The success of Caplin Point is primarily attributed to its unique business model. Starting of as an SME, Caplin Point decided at an early stage that the conventional style of exports would mean diminishing margins and reduced opportunities for expansion, and had taken the unique step of creating last mile logistical solutions for its exclusive distributors across Latin America and various parts of Africa. This way, Caplin Point is able to generate adequate revenue and cash flow to remain debt-free with benchmark receivables, and also continue to invest in state of the art manufacturing facilities from internal accruals. One of the main reasons for the success can be attributed to the wide range of products offered across diverse geographies. Business area of the company Caplin Point is the mid-sized company in India’s pharmaceutical sector to be engaged in the manufacture of APIs, finished formulations, research & development, clinical research, frontend generic presence in Latin America, brand marketing in Francophone Africa and an USFDA approved injectable facility. Products
Awards and recognitions
|
||
Company Profile
Caplin Point Laboratories was established in 1990 to manufacture a range of ointments, creams and other external applications. The Company was listed in 1994; the IPO proceeds were deployed in a manufacturing facility in Pondicherry. The promoters exposed their lives to physical risk when they ventured into war-affected countries more than two decades ago. The Company ventured into the emerging markets of West Africa, Latin America and The Caribbean to market finished formulations. The Company’s asset-light marketing business model has helped generate the resources to build world-class infrastructure.
The success of Caplin Point is primarily attributed to its unique business model. Starting of as an SME, Caplin Point decided at an early stage that the conventional style of exports would mean diminishing margins and reduced opportunities for expansion, and had taken the unique step of creating last mile logistical solutions for its exclusive distributors across Latin America and various parts of Africa. This way, Caplin Point is able to generate adequate revenue and cash flow to remain debt-free with benchmark receivables, and also continue to invest in state of the art manufacturing facilities from internal accruals. One of the main reasons for the success can be attributed to the wide range of products offered across diverse geographies.
Business area of the company
Caplin Point is the mid-sized company in India’s pharmaceutical sector to be engaged in the manufacture of APIs, finished formulations, research & development, clinical research, frontend generic presence in Latin America, brand marketing in Francophone Africa and an USFDA approved injectable facility.
Products
Awards and recognitions
| 1 Day |
|
-2.40% |
| 1 Week |
|
+10.42% |
| 1 Month |
|
-0.90% |
| 3 Month |
|
+1.71% |
| 6 Month |
|
-7.32% |
| 1 Year |
|
+33.74% |
| 2 Year |
|
+144.26% |
| 5 Year |
|
+31.61% |
| 10 Year |
|
| 9 years | 2013-06 | 2014-06 | 2015-06 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | |
| Return on Equity (%) | 40.49 | 53.24 | 55.78 | 43.13 | 54.97 | 49.43 | 37.14 | 29.58 | 25.65 | |
| Return on Capital Employed (%) | 56.69 | 68.99 | 71.11 | 55.41 | 69.03 | 64.08 | 45.59 | 33.35 | 28.82 | |
| Return on Assets (%) | 11.59 | 16.48 | 20.12 | 18.46 | 30.54 | 33.68 | 28.41 | 23.02 | 20.20 |
| Particulars | 10 years | 2013-06 Rs. Cr. | 2014-06 Rs. Cr. | 2015-06 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03* Rs. Cr. |
| Shh. Funds | 43 | 62 | 93 | 128 | 225 | 364 | 633 | 948 | 1,186 | 1,484 | |
| Non Curr. Liab. | 9 | 10 | 10 | 14 | 20 | 28 | 23 | 25 | 17 | 13 | |
| Curr. Liab. | 83 | 108 | 125 | 125 | 113 | 109 | 86 | 144 | 143 | 208 | |
| Minority Int. | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9 | 18 | 26 | |
| Equity & Liab. | 135 | 180 | 229 | 267 | 358 | 500 | 743 | 1,126 | 1,364 | 1,730 | |
| Non Curr. Assets | 96 | 131 | 147 | 149 | 179 | 196 | 249 | 303 | 328 | 432 | |
| Curr. Assets | 39 | 49 | 82 | 119 | 179 | 304 | 494 | 823 | 1,036 | 1,298 | |
| Misc. Exp. not W/O | |||||||||||
| Total Assets | 135 | 180 | 229 | 267 | 358 | 500 | 743 | 1,126 | 1,364 | 1,730 |
| Particulars | 10 years | 2013-06 Rs. Cr. | 2014-06 Rs. Cr. | 2015-06 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. TTM |
| Net Sales | 127 | 173 | 252 | 239 | 402 | 540 | 649 | 863 | 1,061 | 1,269 | |
| Other Income | 2 | 4 | 3 | 4 | 10 | 13 | 19 | 41 | 24 | 39 | |
| Total Income | 129 | 177 | 255 | 242 | 412 | 553 | 668 | 905 | 1,085 | 1,308 | |
| Total Expenditure | -105 | -137 | -192 | -175 | -277 | -345 | -417 | -603 | -733 | -875 | |
| PBIDT | 24 | 40 | 63 | 68 | 135 | 208 | 251 | 301 | 352 | 433 | |
| Interest | -1 | -1 | -1 | 0 | -1 | -1 | -1 | 0 | -2 | -1 | |
| Depreciation | -2 | -4 | -8 | -7 | -13 | -19 | -23 | -32 | -37 | -47 | |
| Taxation | -8 | -10 | -12 | -14 | -25 | -44 | -50 | -54 | -62 | -77 | |
| Exceptional Items | |||||||||||
| PAT | 14 | 26 | 41 | 46 | 96 | 145 | 177 | 215 | 251 | 308 | |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | -9 | -9 | |||
| Share Associate | |||||||||||
| Other Related Items | |||||||||||
| Consolidated Net Profit | 14 | 26 | 41 | 46 | 96 | 145 | 177 | 215 | 242 | 300 | |
| Adjusted EPS | 2 | 3 | 5 | 6 | 13 | 19 | 23 | 28 | 32 | 40 |
| Particulars | 10 years | 2012-06 Rs. Cr. | 2013-06 Rs. Cr. | 2014-06 Rs. Cr. | 2015-06 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
| Cash Fr. Operatn. | 28 | 32 | 60 | 50 | 42 | 68 | 66 | 83 | 45 | 266 | |
| Cash Fr. Inv. | -16 | -45 | -44 | -23 | -6 | -36 | -69 | -100 | -55 | -5 | |
| Cash Fr. Finan. | -1 | -1 | -6 | -9 | -14 | -7 | -12 | 90 | 80 | -24 | |
| Net Change | 10 | -15 | 10 | 19 | 23 | 25 | -14 | 73 | 70 | 236 | |
| Cash & Cash Eqvt | 32 | 17 | 27 | 45 | 68 | 91 | 77 | 151 | 221 | 457 |
|
Thu, 19 May 2022
Spurt in Volume
|
|
|
Thu, 19 May 2022
Spurt in Volume
|
|
|
Wed, 18 May 2022
Record Date
|
| Thu, 19 May 2022 |
Higher Delivery Quantity
|
Higher Trade Quantity
|
Higher Trade and Delivery Quantity
|
Closing Above Previous High
|
Making Higher Highs for 3 days
|
Equities
M.F.
Sectors